Genotyping the donor for the ABCB1 c.1199 G>A (exon 11, rs2229109) allele may be of interest before prescribing tacrolimus to the recipient, although this polymorphism is rather rare and its effect may be limited to certain mechanisms of graft loss.
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clinical research/practice, genomics, graft survival, immunosuppressant -calcineurin inhibitor: tacrolimus, kidney transplantation/nephrology, pharmacology, translational research/science epithelial cells could be associated to a poorer outcome. However, a large study provided discordant results, as the exon 26 (c.3435) wild-type genotype was associated with a decrease in allograft survival compared to the variant genotype (TT) in kidney graft recipients treated by tacrolimus, whereas no association was found in patients on CsA. 9 A fourth ABCB1 SNP, in exon 11 (c.1199G > A), leading to an amino-acid change in a region close to the substrate recognition domain, modified the efflux of CNI and other drugs from isolated cells or tissues, with substrate-dependent differences. [10] [11] [12] The 1199A variant was associated with increased tacrolimus concentration in peripheral mononuclear and liver cells as compared to the reference allele. 11, 12 The hypothesis that this SNP decreases the P-gp mediated efflux of tacrolimus was further confirmed in vitro using two independent cell lines. 10 The variant allele also associated with 1.8-fold higher CsA concentration in the mononuclear cells of transplant recipients (n = 64) as compared to the reference allele, 13 but could not be confirmed in vitro. Association studies between this particular SNP and long-term CNI outcomes in renal transplantation are still missing.
On the other hand, CYP3A4 and CYP3A5 account for most of the metabolism of tacrolimus and have been long considered as two other major determinants of CNI pharmacokinetics. 14 The most studied SNP in CYP3A5 is a A > G substitution located in intron 3 (CYP3A5*3; rs35599367) leading to a truncated protein. 15 In Caucasians, 85% to 97% of individuals are homozygous carriers of the variant (CYP3A5*3) allele and thus classified as "non-expressers." 16 The effect of this variant on tacrolimus dose requirement is well established, 16 but its consequence on longterm outcomes is currently more controversial, with no difference at 5 years posttransplantation regarding the risk of biopsy-proven acute rejection (BPAR), drug adverse effects (cancer, cardiovascular disorders or infections), or renal dysfunction between patient treated with a standard or a genotype-adjusted dose. 17, 18 Regarding CYP3A4, the most interesting variant allele is CYP3A4*22, which leads to a decrease in hepatic mRNA levels and in vitro enzyme activity. 19 It was also associated with a significant increase of tacrolimus dose-normalized trough concentrations in renal transplant patients, independently of the CYP3A5*3 effect. 20 Its effect in the long term is currently unknown.
In this context, the objective of this work was to investigate, in two large cohorts of French kidney transplants recipients treated with tacrolimus, the influence of donor and recipient ABCB1, CYP3A4, and CYP3A5 genotypes on the risk of allograft loss.
| MATERIAL AND ME THODS

| Study design
This retrospective cohort study relied on the clinical data on file, and the donor and recipient DNA of two independent populations of adult renal transplant patients receiving a tacrolimus-based im- 
| Identification of genotypes
Recipient genotypes for CYP3A4 rs35599367-C>T (CYP3A4*22 allele), CYP3A5 rs776746-A>G (CYP3A5*3 allele), and both donor and recipient genotypes for ABCB1 c.3435C>T (exon 26, rs1045642), ABCB1 c.1236 C>T (exon 12, rs1128503), ABCB1 c.2677 G>T (exon 21, rs2032582), and c.1199 G>A (exon 11, rs2229109) were determined using Taqman allelic discrimination assays performed with a Rotorgene Q instrument (Qiagen) using the manufacturer protocol.
| Outcome definition and covariates investigated
Allograft loss was defined as a death-censored return to dialysis.
In the replication cohort, return to dialysis was analyzed in three ways: all causes, due to chronic rejection (interstitial fibrosis/ tubular atrophy without antibodies), and due to humoral rejection (donor specific antibodies). The covariates investigated in the development dataset were: the number of previous transplantations, the recipient and donor age and sex, the type of donation (living or deceased), the number of HLA mismatches, the cold ischemia time (hours), the time to allograft function recovery (days), the number of dialyses in the first week after transplantation, the occurrence of acute rejection episodes (0 vs. ≥1).
| Statistical analyses
Statistical analyses were performed using R software version 3.2.4
(R foundation for statistical computing, http://www.r-project.org).
Deviations from the Hardy-Weinberg equilibrium and the most probable haplotypes were inferred using the "SNPassoc" package. For association analyses related to SNPs and haplotypes, the most frequent allele was considered the reference. In case of allelic frequency lower than 5%, a recessive genetic model was applied, and a codominant genetic model otherwise. The effect of gene polymorphisms (SNPs or haplotypes) on allograft loss was investigated using the Cox proportional hazard model using the "survival" package. A classical approach was used: each covariate was first tested in univariate analysis and then all those characterized by a P-value less than .05 were included simultaneously in an intermediate multivariate model. The significance of variables in the final model was tested by a backward stepwise process using the akaike criteria (AIC) to evaluate the effect of omitting variables. The robustness of the final model was internally evaluated by performing 1000 bootstraps of the initial dataset. The proportionality of risks in the final model was assessed using Schoenfeld residuals. For the significant polymorphisms, time-to-event data were estimated using Kaplan-Meier analysis for a patient with or without the polymorphism of interest and groups were compared using the log-rank test.
The covariates significantly associated with the outcome in the discovery population were investigated in the replication study using multivariate analysis. TA B L E 1 (Continued)
TA B L E 1 Patient characteristics in the discovery and replication datasets
| RE SULTS
The characteristics of the patients in the discovery (n = 330) and the replication (n = 369) populations are given in Table 1 . No deviation from the Hardy Weinberg equilibrium was observed for the SNPs investigated and their frequencies were consistent with previous reports. 6, 16, 20 As expected, strong linkage disequilibrium was found between exon 12, 21, and 26 SNPs leading to a common haplotype distribution (Supplemental Figure S1) . A recessive genetic model was applied for CYP3A4*22, CYP3A5*3, and ABCB1 c.1199 G>A. Results of the univariate and multivariate analyses of the determinants of allograft loss are presented in Table 2 . None of the recipient genetic variation in CYP3A or ABCB1 was associated with allograft loss. The number of successive transplantations, the donor ABCB1 c.1199
GA/AA genotype, and the time-to-allograft function recovery were significantly associated with allograft loss in the discovery dataset.
TA B L E 2 Univariate and multivariate analyses of the risk of graft loss in the discovery and replication datasets the robustness of the final model was internally evaluated by performing 1000 bootstraps of the initial dataset followed by backward stepwise selection of final models using the R package bootStepAIC. 23 The %bootstrap selection represents how many times each variable was selected during the bootstrap process. After Bonferonni correction for multiple testing in the validation dataset, a P value threshold of .05/3 = .0166 was retained for statistical significance.
(Continues)
Bootstrap analyses tend to support these results (Table 2 ). However, none of these associations was confirmed by multivariate analysis of the replication dataset, when investigating all allograft losses together. When investigating specifically allograft losses due to chronic rejection, a significant association with the number of previous transplantations was found, while for allograft losses due to humoral rejection episodes, it was the donor ABCB1 c.1199 GA/AA genotype that was significant (Table 2) , even after Bonferroni correction for multiple testing (P = .05/3 = .0166). In this latter case, the hazard ratios were in favor of an increased risk of graft loss associated to the A variant allele (GA or AA genotype). The survival curves as a function of the donor ABCB1 c.1199 GA/AA genotype in the development and in the replication cohorts are presented in Figure 1 . No deviation of risk proportionality was observed in the final models. 
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| D ISCUSS I ON
In this large retrospective study relying on two independent populations of renal transplant patients, we investigated whether candidate SNPs in the donor CYP3A and the donor and recipient ABCB1
could influence long-term allograft outcome. We found that the donor ABCB1 c.1199 variant genotype increased the risk of allograft loss in the development dataset, which could not be exactly confirmed in the replication dataset, where it was only significant in patients with allograft loss attributed to humoral rejection episodes. Retransplantation was another determinant of allograft loss, whereas the time-to-graft function recovery was a significant risk factor in the discovery cohort only.
To the best of our knowledge, this is the first time the association between this SNP and graft loss or ABMR is described. Interestingly, among the groups who investigated the effects of donor genetic variations on allograft survival or chronic histological damage, neither Naesens et al 8 nor Ma et al 5 investigated the effect of this particular SNP in ABCB1. Moore et al did, and they did not find any significant association, but their discovery cohort contained only CsA-treated patients. 9 Consistently, Dessilly et al showed in vitro using two different cell lines (HEK-293 and K562) that the effect of this SNP is substrate-specific: the variant allele decreases the P-gp mediated efflux of tacrolimus, but not CsA. 10 The shorter allograft survival we The number of patients given tacrolimus or CsA was not reported and all patients were gathered in the same analysis (no development and replication dataset). When stratification using donor ethnicity was applied, the authors found that the effect of ABCB1 3435TT
was only visible in recipients of a European-American donor. While ethnicity obviously affects the frequency of the variant allele, it can hardly explain the difference in SNP effects. Finally, the authors concluded that discrepancies between their and previous studies could reflect unique environmental exposures between centers or kidney donors. 5 It is currently difficult to draw any conclusion about the effect of ABCB1 SNPs on allograft outcomes. While CNI-specific differences due to the different tubular toxicity mechanisms between tacrolimus and CsA might be anticipated, the literature does not allow us to draw such conclusions.
In the present study, CYP3A4*22 and CYP3A5*3 alleles were not significantly associated with the risk of allograft loss, which tends to corroborate recent prospective cohort studies 17, 18 showing no association with the risk of biopsy-proven acute rejection, drug adverse effects, or renal function deterioration.
A limitation of the present study is the difference in follow-up duration between patients in the discovery and replication groups Different and cumulated mechanisms can be involved in graft loss, depending of the time after transplantation. For instance, we previously observed that the genotype-related difference in allograft loss linked to nephrotoxicity appears after 5 years. 6 In addition, the low frequency of the ABCB1 c.1199 G>A observed in Europeans (mutated allele frequency of 3.3%) 22 has to be considered as a difficulty for the replication of the findings. As the study was conducted in France, we can only hypothesize that most of the patients were of "Caucasian" ancestry. Other (minor) ancestries may have added some random noise, but probably not more than diet or other environmental conditions, which were not collected either. These results are only usable for EUR and AMR for whom the frequencies of the variant allele are similar (~3%). However, an important concern is how the ethnicity is collected. Is it only declarative? Is it based on the phenotype (skin color, skeleton anatomy, geographic origin, individual preference, others)? For the first generations it might be straightforward, but as France has been a melting pot of many populations over the centuries, it is very difficult to establish a particular ancestry for some patients. Finally, we cannot exclude that other transporters of the ABC or SLC (families expressed in the kidney (eg, MRP2, MRP4, MATE) are involved in tacrolimus transport (although probably to a small extent), but it cannot question the present results: it would have increased the variability in the two G1199A groups and made the finding of its association with outcome more difficult, rather than favoring a false-positive association.
The present study was a candidate-gene (ie, hypothesis-driven)
and not an untargeted, whole exome or whole genome study. As largely reported in the literature, the goal of a candidate-gene study is to investigate the association between a single or a few SNPs and complex outcomes. To discover new pharmacogenes or new variants associated with clinical outcomes would require sequencing the whole genome or of a number of genes of interest for instance. However, this would require thousands of patients to identify a statistically significant association with outcomes, owing to the generally low frequency and low penetrance of such genetic variations/mutations.
Alternatively, this would require selecting patients with extreme phenotypes (very low frequency-high penetrance hypothesis). The study reported here was not designed for, and is not suited to, this objective.
If the recipient DNAs were not analyzed in the validation dataset, while both the donor and recipient DNAs were taken into account in the first cohort, it is because the validation dataset was only Otherwise, the covariates collected in the development and replication cohorts were the same.
Genotyping the donor for the ABCB1 c.1199 G>A (exon 11, rs2229109) allele may be of interest as part of the screening before initiation of tacrolimus treatment, although it is rather rare and its effect may be limited to certain mechanisms of graft loss.
This should not result in excluding donors carrying this allele, but rather in personalizing further graft attribution (eg, avoiding attributing the kidneys to hyper-immunized recipients who will require high tacrolimus exposure) or the immunosuppressive regimen in the recipient (eg, favor other drugs such as belatacept or cyclosporine).
In conclusion, the ABCB1 c.1199 G>A (exon 11, rs2229109) allele was associated with an increased risk of allograft loss in the discovery cohort but this effect was not validated in the replication cohort, where the effect of this variant was only found in patients with graft loss due to humoral rejection. With the advent of Next-Generation Sequencing (NGS) in medicine, which makes full genomic information accessible at constantly decreasing cost, it is likely that donor genotypes for such important pharmacogenes will be available soon in a vast majority of transplantation centers, so that the question is more about how to interpret this SNP than whether to characterize it or not. In the NGS era, candidate It is obviously still difficult to know if the results of P-gp variations will be useful for patient care, but considering the importance of the risk observed in the present study (HR of about 3 for graft loss in the discovery cohort on tacrolimus) as well as in a previous one 
